drugset / Trial / NCT00360295

A Trial Of Azithromycin SR For The Treatment Of Mild To Moderate Community Acquired Pneumonia In Japanese Adults

NCT00360295

Phase 3 Completed 153 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the clinical efficacy and safety in patients with mild or moderate community-acquired pneumonia receiving a dose of 2 g of azithromycin in the SR formulation.

Timeline

Start
2006-09
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 2 g

Indications